Prof John McMurray presents at the ESC Congress 2021

Professor McMurry presented data from DAPA-CKD and DAPA-HF Phase III trials demonstrating the beneficial effects of Farxiga (dapagliflozin) on kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) and heart failure (HF), two interrelated diseases with devastating impact for patients.

Abstract available on the ESC Congress Research Gateway

The paper was simultaneously published and available here:


Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

John J.V. McMurray, MD,a David C. Wheeler, MD,b,c Bergur V. Stefánsson, MD,d Niels Jongs, MSC, e Douwe Postmus, PHD,f Ricardo Correa-Rotter, MD,g Glenn M. Chertow, MD,h Fan Fan Hou, MD,i Peter Rossing, MD,j,k C. David Sjöström, MD,d Scott D. Solomon, MD,l Robert D. Toto, MD,m Anna Maria Langkilde, MD,d Hiddo J.L. Heerspink, PHD,c,e on behalf of the DAPA-CKD Trial Committees and Investigators


The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF).


Patients with CKD, with and without type 2 diabetes, were enrolled in the DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial. Some patients had HF at baseline.


Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CKD patients with or without type 2 diabetes, independently of history of HF. (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease [DAPA-CKD]; NCT03036150) (J Am Coll Cardiol HF 2021;-:-–-) © 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://

First published: 1 September 2021